Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months

Margatho, Deborah; Carvalho, Nelsilene Mota; Bahamondes, Luís

doi:10.1080/13625187.2020.1725461

Cited by 23 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 6 months follow up, there were 68% reduction of pain in ENG implant group and 53% in DMPA group [10]. Study comparing effectiveness of ENG implant and LNG IUS showed similar result [11]. Data regarding use of LNG In our case, patient had undergone surgery to remove right endometrial cyst.…”

Section: Introductionsupporting

confidence: 56%

Non-contraceptive Effects of Subdermal Levonogestrel Implant on Endometriosis Patient : A Case Report

Pasidri

2021

AJBSR

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 56%

Non-contraceptive Effects of Subdermal Levonogestrel Implant on Endometriosis Patient : A Case Report

Pasidri

2021

AJBSR

View full text Add to dashboard Cite

show abstract

“…Ferrero et al [212] demonstrated the efficacy of ENG-releasing implant in treating symptoms related to RV endometriosis (non-menstrual pelvic pain, deep dyspareunia, dysmenorrhea, dyschezia) with a high 2-year continuation rate (93.0%); interestingly, at 6-month follow-up, the volume of the RV nodules was significantly lower compared with the baseline; a further decrease was also observed at 12-and 24-month follow-up [212]. In ENG implant users, a reduction in biomarkers of endometriosis (CA-125, CD23, endometrial nerve fibre density) was also observed [213,214].…”

Section: Endometriosismentioning

confidence: 89%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years.

show abstract

“…Decreased blood flow and downregulation of oestrogen receptors in glandular and stromal endometrial tissue leads to atrophy and shrinkage of adenomyosis foci in the myometrium. This allows myometrium to contract better and decreases blood loss and the size of the uterus [2,5,7,17] . Endometrial hyperplasia may be simple or complex, with or without atypia, is another indication where LNG-IUS is being used with 100% response rate.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of non-contraceptive benefits of LNG-IUS: A clinical study

Anju¹,

Kaur²,

Gupta³

2022

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

Introduction: IUCDs are the most widely used and effective contraceptive methods and are safe. Huge variety of IUCDs are available which include inert, copper containing, and medicated with levonorgestrel or indomethacin. LNG has been explored for its non-contraceptive benefits by various researchers and found to be effective for women and adolescents as first line therapy with heavy menstrual bleeding and is associated with improved dysmenorrhoea.so we did a two year perspective study in deptt of obs and gynae at GMC Patiala to assess the role of LNG-IUS IN various gynaecological indication otherthan contraception. Material and Methods: Women with heavy menstrual period, dysmenorrhea or both who reported in the OPD were examined, including breast and pelvic examination. USG was done to note various pathologies like fibroid, endometriosis, endometrial hyperplasia, adenomyosis and functional ovarian cyst. This was followed by endometrial biopsy. After the biopsy report was available, decision for LNG-IUS insertion was taken. LNG-IUS was inserted, under all sterile conditions without anaesthesia. After insertion, patient was followed up at 1-, 3-, 6-and 12-month interval for menstrual pattern change any complications compliance on part of patient. Results: A total of 30 patients were enrolled over a period of two years. 28 patients were in the age group 30-50 years and only 2 patients were post-menopausal. 56.6% had rural background, 43% were illiterate and 83.3% were multipara. In 50% of the women, the chief complaint was heavy menstrual bleeding with dysmenorrhea and 36% had heavy menstrual bleeding alone. 6.6% had dysmenorrhea alone and another 10% reported with irregular bleeding. According to PALM-COIEN classification, AUB-A was diagnosed in 16.6%, AUB-L in 30%, AUB-O in 40%, AUB-M in 3.3%, endometriosis in 13.3%. LNG-IUS was not used as contraception or HRT in any of the cases. On post insertion follow up after one month, 90 percent had relief from heavy menstrual bleeding. At sixmonth follow-up, 23.3% reported spotting and 60% reported normal flow during periods. After one year 73.9% patient had normal flow and 13% patients achieved amenorrhoea. The irregular bleeding or spotting was managed by giving supportive therapy in form of reassurance in 30%, NSAIDS in 16.6%, and norethisterone in 46.6%. Ormeloxifene and OCPs were given in 3.3% each and response was satisfactory. At one year follow up it was seen that 76.6% patients continued with LNG IUS and found it comfortable with enhanced quality of life. Conclusion: LNG-IUS is a better choice for the management of endometrial hyperplasia simple or complex, with or without atypia, AUB, adenomyosis and endometriosis. LNG-IUS can be a good alternative to hysterectomy.

show abstract

Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months

Cited by 23 publications

References 31 publications

Non-contraceptive Effects of Subdermal Levonogestrel Implant on Endometriosis Patient : A Case Report

Non-contraceptive Effects of Subdermal Levonogestrel Implant on Endometriosis Patient : A Case Report

Safety and Benefits of Contraceptives Implants: A Systematic Review

Evaluation of non-contraceptive benefits of LNG-IUS: A clinical study

Contact Info

Product

Resources

About